Press Releases
May 12, 2022

Abstracts represent exciting research progress across four cancers where patients have limited treatment options TOKYO, May 12, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO:

May 5, 2022

Astellas' investigational nonhormonal treatment meets all primary endpoints, significantly reducing the frequency and severity of vasomotor symptoms associated with menopause TOKYO, May 5, 2022...

Apr 25, 2022

- Addressing everyday challenges in cancer care; apply by June 3, 2022 - NORTHBROOK, Ill., April 25, 2022 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") today announced that it is accepting...

EXPLORE ALL US PRESS RELEASES

Articles
Apr 28, 2022

Astellas is proud to share recent top leadership promotions and appointments across our divisions for employees based in the US. These leaders are all crucial in driving forward the company’s...

Feb 15, 2022

At Astellas, raising awareness among employees of the many contributions of Black Americans to history and culture is a top priority for Black History Month in partnership with our African...

EXPLORE ALL ARTICLES

Stay Connected

Get only the email alerts you want.

Subscribe

Media Contacts

corporate.communications@astellas.com

800-888-7704
(press menu option 5, then option 2)
This line is monitored between 8:00am-4:30-pm Central Time M-F

For inquiries during non-business hours, please contact us

 

Astellas on Twitter
Download Fact Sheet
Sustainability
Investors
Explore U.S. Products